Explore the Agenda
7:50 am Check-In & Coffee
8:50 am Chair’s Opening Remarks
Commercial Readiness & Global Harmonisation: Demystifying the Strategies for Widespread Clinical Success & Regulatory Approval
Getting radiopharmaceuticals to patients is about more than just approvals. This session evaluates the strategies needed to launch successfully and navigate global regulations with confidence
9:00 am Understanding Global Differences in TRP Procedure & Regulation to Gain Harmonisation for Worldwide Administration
Getting radiopharmaceuticals to patients is about more than just approvals. This session evaluates the strategies needed to launch successfully and navigate global regulations with confidence.
- Comparing procedural and regulatory differences in TRP use across major global markets
- Highlighting key challenges in harmonising clinical standards, manufacturing, and approval pathways
- Discussing strategies to align stakeholders and streamline international TRP administration
9:30 am Panel Discussion – Challenges & Opportunities for Securing Ongoing Funding for Radiopharmaceuticals
- Assessing differences in US and European markets
- Understanding the nuances in European market to appreciate what investors are looking for
- Hearing directly from investors about their priorities to secure new funding
10:30 am Morning Break & Networking
Discovery & Preclinical Track
Discovery & Preclinical Track
Chair: John Babich, Chief Scientific Officer, Ratio Therapeutics
Peptides, Antibodies, Microspheres & More: Targeting Molecule Selection Strategies
11:30 am Introducing a Tumour Agnostic Pre-Targeted Radiotherapeutic Platform to Target Tumour Associated Macrophages
Chief Scientific Officer, OncoOne
- Pretargeting to increase therapeutic windows in RLTs
- OncoOne’s Pretarg-it® platform
- Data from preclinical tumor models and outlook
12:00 pm Targeting ALDH1A1 for the Identification & Treatment of Therapy Resistant Cancers
Chief Scientific Officer, Nuclide Therapeutics
- Targeting the cancer stem cell marker – AzLDH1A1
- Identifying refractory disease with our first-in-class theranostic, [18F]NTx-10
- Treating therapy-resistant non-small cell lung cancer with [131I] NTx-11
Translational & Clinical Development Track
CMC & Sourcing Track
12:30 pm Lunch
Discovery & Preclinical Track
Targeting Moiety Engineering: Gaining Competitive Differentiation Through Optimised Molecular Design
1:30 pm Internalisation of Targeted Radiopharmaceuticals: Strategic Imperative or Situational Choice?
Chief Scientific Officer, OranoMed
- DARPin optimizations to achieve an RLT suitable profile via iterative design – test cycles
- Integrating of these insights for optimized lead selection of the next programs
- How this differs from standard RLT vector development and allows to optimize timelines, costs, resources
2:00 pm Exploring Peptide Engineering for Improved Activity & Survival Alongside Radioisotopes
Chief Executive Officer, Singzyme
- Engineering peptides to improve tissue penetration and receptor binding, thereby increasing tumour uptake and retention of radioisotopes
- Modifying peptide stability and clearance rates to extend half-life and reduce systemic toxicity, enhancing therapeutic efficacy.
- Designing peptides to deliver radioisotopes directly to tumour sites, maximising localised radiation delivery and minimising damage to healthy tissues
2:30 pm Targeted Delivery of Radioisotopes to Solid Tumours Using Bicyclic Radionuclide Conjugates Directed at Novel Tumor-Associated Antigens
Director, Bicycle Therapeutics plc
- Explaining how screening platforms can identify novel peptide binders to challenging targets and optimise them into highaffinity, selective molecules
- Highlighting the creation of targeted radionuclide conjugates aimed at MT1-MMP and EphA2 for precision therapy
- Presenting preclinical findings on proteins widely expressed across cancers with significant unmet clinical needs
Translational & Clinical Development Track
CMC & Sourcing Track
3:00 pm Afternoon Break
Driving TRP Innovation: Broadening Target Landscapes & Advancing Clinical Applications
3:30 pm Assessing Future Directions for Addressing Unmet Medical Need by Expanding Indications & Selecting Novel Targets
- Identifying existing targets to be adapted to radiopharmaceuticals
- Exploring areas of unmet need and market potential
- Uncovering market predictions for novel tumour applications and expansion
4:00 pm Expanding TRP Therapy into Neuroendocrine Tumours: Targeting SSTR2 with 212Pb
- Discussing Orano Med’s unique approach to TAT with 212Pb
- Presenting the latest updates on 212Pb-DOTAMTATE
- Exploring Orano Med’s portfolio of 212Pb-based TATs